- Home
- GWRS vs RIGL Comparison
GWRS vs RIGL Comparison
Compare GWRS & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GWRS
- RIGL
- Stock Information
- Founded
- GWRS 2003
- RIGL 1996
- Country
- GWRS United States
- RIGL United States
- Employees
- GWRS N/A
- RIGL N/A
- Industry
- GWRS Water Supply
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- GWRS Utilities
- RIGL Health Care
- Exchange
- GWRS Nasdaq
- RIGL Nasdaq
- Market Cap
- GWRS 286.0M
- RIGL 335.5M
- IPO Year
- GWRS 2010
- RIGL 2000
- Fundamental
- Price
- GWRS $10.16
- RIGL $18.93
- Analyst Decision
- GWRS
- RIGL Buy
- Analyst Count
- GWRS 0
- RIGL 5
- Target Price
- GWRS N/A
- RIGL $36.40
- AVG Volume (30 Days)
- GWRS 50.6K
- RIGL 192.9K
- Earning Date
- GWRS 08-06-2025
- RIGL 08-05-2025
- Dividend Yield
- GWRS 2.99%
- RIGL N/A
- EPS Growth
- GWRS N/A
- RIGL N/A
- EPS
- GWRS 0.23
- RIGL 2.08
- Revenue
- GWRS $53,539,000.00
- RIGL $203,077,000.00
- Revenue This Year
- GWRS $8.31
- RIGL $14.41
- Revenue Next Year
- GWRS $6.52
- RIGL $15.97
- P/E Ratio
- GWRS $44.21
- RIGL $9.09
- Revenue Growth
- GWRS 3.94
- RIGL 70.16
- 52 Week Low
- GWRS $9.37
- RIGL $7.48
- 52 Week High
- GWRS $13.98
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- GWRS 45.02
- RIGL 44.97
- Support Level
- GWRS $10.05
- RIGL $18.24
- Resistance Level
- GWRS $10.59
- RIGL $19.35
- Average True Range (ATR)
- GWRS 0.27
- RIGL 0.90
- MACD
- GWRS -0.03
- RIGL -0.14
- Stochastic Oscillator
- GWRS 15.54
- RIGL 23.44
About GWRS Global Water Resources Inc.
Global Water Resources Inc operates as a water resources management company that owns, operates, and manages water, wastewater, and recycled water utilities in strategically located communities, principally in metropolitan Phoenix, Arizona. It operates within the State of Arizona.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.